[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Kozak KR, Mahadevan A, Moody JS: Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol; 2009 Apr;11(2):183-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome.
  • The epidemiology and natural history of adult gliosarcomas (GSMs), as well as patient and treatment factors associated with outcome, are ill defined.
  • [MeSH-major] Brain Neoplasms / epidemiology. Gliosarcoma / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Outcome Assessment (Health Care). Prognosis. Radiotherapy, Adjuvant. SEER Program. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1993 May;78(5):767-75 [8468607.001]
  • [Cites] Pediatr Neurosurg. 1993 Mar-Apr;19(2):57-62 [8443097.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2910-8 [7773942.001]
  • [Cites] Br J Neurosurg. 1995 Apr;9(2):171-8 [7632363.001]
  • [Cites] Indian J Med Res. 1997 Sep;106:229-35 [9378529.001]
  • [Cites] J Neurosurg. 1998 Sep;89(3):425-30 [9724117.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Jun;100(2):153-9 [9746306.001]
  • [Cites] Am J Pathol. 1955 Jul-Aug;31(4):633-53 [14388124.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):59-63 [16078109.001]
  • [Cites] Clin Neurol Neurosurg. 2006 Feb;108(2):178-86 [16412839.001]
  • [Cites] Acta Oncol. 2007;46(8):1202-4 [17851847.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):57-64 [11578729.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):467-73 [12959431.001]
  • [Cites] J Neurosurg. 1976 Oct;45(4):398-408 [956876.001]
  • [Cites] J Neuropathol Exp Neurol. 1978 May;37(3):300-13 [660217.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 Jan-Feb;8(1):117-22 [3101453.001]
  • [Cites] Cancer. 1991 May 1;67(9):2342-9 [1849447.001]
  • [Cites] Neurosurgery. 1991 Sep;29(3):385-8; discussion 388-9 [1833663.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • (PMID = 18780813.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2718990
  •  go-up   go-down


2. Ayadi L, Charfi S, Khabir A, Kalle R, Sellami A, Makni S, Boudawara Z, Sellami-Boudawara T: [Cerebral gliosarcoma: clinico-pathologic study of 8 cases]. Tunis Med; 2010 Mar;88(3):142-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cerebral gliosarcoma: clinico-pathologic study of 8 cases].
  • Pathological exam including histochemical and immunohistochemical study confirmed the diagnosis of gliosarcoma in all cases.
  • [MeSH-major] Brain Neoplasms / pathology. Gliosarcoma / pathology
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20415184.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


3. Han SJ, Yang I, Ahn BJ, Otero JJ, Tihan T, McDermott MW, Berger MS, Prados MD, Parsa AT: Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients. Cancer; 2010 Mar 1;116(5):1358-66
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients.
  • BACKGROUND: Primary gliosarcoma (PGS) is a rare central nervous system tumor with limited experience reported in the literature.
  • Patients with gliosarcomas resembling meningioma were found to have a significantly prolonged median survival compared with patients harboring gliosarcoma resembling glioblastoma multiforme (16 months vs 9.6 months; P = .011).
  • [MeSH-major] Brain Neoplasms / therapy. Gliosarcoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20052717.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


Advertisement
4. Oshiro S, Tsugu H, Komatsu F, Ohmura T, Ohta M, Sakamoto S, Fukushima T, Inoue T: Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer Res; 2009 Mar;29(3):911-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The subjects comprised ten patients with high-grade glioma [glioblastoma multiforme (GBM), n=3, gliosarcoma (GS), n=1, anaplastic oligodendroglioma (AO), n=3, anaplastic mixed oligoastrocytoma (AOA), n=1, and anaplastic ependymoma (AE), n=2].
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Gliosarcoma / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Treatment Outcome. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414327.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


5. Gorbacheva IuV, Baranova OV, Shishkina LV, Pal'tseva EM, Egorov OE, Evzikova GIu, Timoshenkov AV: [Multiple gliosarcoma metastases in the cauda equina roots]. Arkh Patol; 2010 Jul-Aug;72(4):52-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple gliosarcoma metastases in the cauda equina roots].
  • The authors report a rare a case of gliosarcoma metastases in a 28-year-old male patient.
  • Gliosarcoma was diagnosed, by taking into account morphological and immunohistochemical data.
  • [MeSH-major] Brain Neoplasms. Cauda Equina / pathology. Gliosarcoma. Peripheral Nervous System Neoplasms
  • [MeSH-minor] Adult. Glial Fibrillary Acidic Protein / metabolism. Humans. Male. Neoplasm Metastasis. Neoplasm Proteins / metabolism. Vimentin / metabolism

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086641.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Neoplasm Proteins; 0 / Vimentin
  •  go-up   go-down


6. Nishi N, Kawai S, Yonezawa T, Fujimoto K, Masui K: Early appearance of high grade glioma on magnetic resonance imaging. Neurol Med Chir (Tokyo); 2009 Jan;49(1):8-12
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients underwent surgical tumor resection and the histological diagnoses were all high grade gliomas, glioblastomas in five, gliosarcoma in one, and anaplastic astrocytoma in one.
  • Surveillance MR imaging should be performed at short intervals in adult patients presenting with seizures but with no or minimal abnormalities on initial MR imaging to identify progression of high grade glioma at the earliest opportunity.
  • [MeSH-minor] Aged. Astrocytoma / diagnosis. Astrocytoma / pathology. Disease Progression. Dizziness / etiology. Early Diagnosis. Fatal Outcome. Female. Gliosarcoma / diagnosis. Gliosarcoma / pathology. Humans. Male. Middle Aged. Seizures / etiology

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168996.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Kumar P, Singh S, Kumar P, Krishnani N, Datta NR: Gliosarcoma: an audit from a single institution in India of 24 post-irradiated cases over 15 years. J Cancer Res Ther; 2008 Oct-Dec;4(4):164-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliosarcoma: an audit from a single institution in India of 24 post-irradiated cases over 15 years.
  • Outcomes in gliosarcoma are poor despite multimodality management.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Gliosarcoma / radiotherapy
  • [MeSH-minor] Adult. Clinical Trials as Topic. Female. Humans. India. Male. Medical Oncology / methods. Middle Aged. Models, Statistical. Treatment Outcome

  • Genetic Alliance. consumer health - Gliosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19052388.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


8. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol; 2009 Feb 1;27(4):579-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
  • PURPOSE: This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and gliosarcoma.
  • PATIENTS AND METHODS: Sixty-five eligible adults with newly diagnosed GBM or gliosarcoma were enrolled.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7841-50 [16278407.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1192-9 [16626884.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 May;61(6):1059-67 [17694310.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1442-53 [10598712.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7 [15380566.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13 [1584765.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):207-18 [10454198.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1454-9 [15817350.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • (PMID = 19075262.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / 2 P50 CA097257
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; DA87705X9K / Erlotinib Hydrochloride
  • [Other-IDs] NLM/ PMC2645859
  •  go-up   go-down


9. Chen JH, Chen KY, Ma HI, Yu CP, Nieh S, Lee HS, Jin JS: Cortactin, fascin and survivin expression associated with clinicopathological parameters in brain gliosarcoma. Chin J Physiol; 2010 Aug 31;53(4):234-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cortactin, fascin and survivin expression associated with clinicopathological parameters in brain gliosarcoma.
  • Gliosarcoma is a very rare primary neoplasm of the central nervous system classified as a variant of glioblastoma.
  • Cortactin, fascin and survivin have been found in several human cancers to play important roles in tumor progression, but the expression pattern of these biomarkers in gliosarcoma is unclear.
  • Immunostaining for cortactin, fascin and survivin was assessed in 6 surgical specimens of brain gliosarcoma, and the relationship between the expression of these biomarkers and tumor size or clinical parameters were examined.
  • Five of our six patients with gliosarcoma survived 3-17 months.
  • Our results demonstrated that over-expression of cortactin, fascin and survivin is associated with malignant transformation of brain gliosarcoma.
  • Development of drugs that target cortactin, fascin and survivin expression may be therapeutic to patients with gliosarcoma.
  • [MeSH-major] Brain Neoplasms / pathology. Carrier Proteins / analysis. Cortactin / analysis. Gliosarcoma / pathology. Inhibitor of Apoptosis Proteins / analysis. Microfilament Proteins / analysis
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21793333.001).
  • [ISSN] 0304-4920
  • [Journal-full-title] The Chinese journal of physiology
  • [ISO-abbreviation] Chin J Physiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Carrier Proteins; 0 / Cortactin; 0 / Inhibitor of Apoptosis Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


10. Charfi S, Ayadi L, Khabir A, Daoud E, Kallel R, Kharrat O, Mnif Z, Boudawara Z, Makni S, Boudawara T: Gliosarcoma with osteosarcomatous features: a short illustrated review. Acta Neurochir (Wien); 2009 Jul;151(7):809-13; discussion 813
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliosarcoma with osteosarcomatous features: a short illustrated review.
  • INTRODUCTION: Gliosarcoma is a rare, malignant, biphasic brain tumor formed by both glioblastoma and sarcomatous components.
  • OBJECTIVE: We report a case of gliosarcoma with osteosarcomatous features in a 33-year-old woman.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiography. Gliosarcoma / pathology. Gliosarcoma / radiography. Osteosarcoma / pathology. Osteosarcoma / radiography
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Brain / pathology. Brain / radiography. Brain / surgery. Cell Proliferation. Ectoderm / metabolism. Ectoderm / pathology. Fatal Outcome. Female. Glial Fibrillary Acidic Protein / analysis. Glial Fibrillary Acidic Protein / metabolism. Glioblastoma / pathology. Glioblastoma / radiography. Glioblastoma / surgery. Headache / etiology. Humans. Male. Mesoderm / metabolism. Mesoderm / pathology. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Neurosurgical Procedures. Prognosis. Radiotherapy. Reoperation. Survival Rate. Vision, Low / etiology. Vomiting / etiology

  • Genetic Alliance. consumer health - Gliosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19399365.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein
  • [Number-of-references] 21
  •  go-up   go-down


11. Pakos EE, Goussia AC, Zina VP, Pitouli EJ, Tsekeris PG: Multi-focal gliosarcoma: a case report and review of the literature. J Neurooncol; 2005 Sep;74(3):301-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-focal gliosarcoma: a case report and review of the literature.
  • Gliosarcoma (GS) is an uncommon malignant brain tumor with biphasic tissue pattern consisted of both glial and sarcomatous components.
  • It usually occurs in adult population of middle age.
  • [MeSH-major] Brain Neoplasms / pathology. Gliosarcoma / pathology

  • Genetic Alliance. consumer health - Gliosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086111.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Han SJ, Yang I, Otero JJ, Ahn BJ, Tihan T, McDermott MW, Berger MS, Chang SM, Parsa AT: Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients. J Neurosurg; 2010 May;112(5):990-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
  • OBJECT: Gliosarcoma can arise secondarily, after conventional adjuvant treatment of high-grade glioma.
  • The current literature on the occurrence of secondary gliosarcoma (SGS) after glioblastoma multiforme (GBM) is limited, with only 12 reported cases.
  • METHODS: Gliosarcoma cases were identified using the University of California, San Francisco's Departments of Neurological Surgery and Neuropathology databases.
  • Through a retrospective chart review, cases of gliosarcoma were considered SGS if the following inclusion criteria were met:.
  • 1) the patient had a previously diagnosed intracranial malignant glioma that did not have gliosarcoma components; and 2) the histopathological tissue diagnosis of the recurrence confirmed gliosarcoma according to the most current WHO criteria.
  • Three patients received radiotherapy alone, 1 patient was treated with chemotherapy alone, and 1 patient's tumor rapidly recurred as gliosarcoma, requiring surgical intervention prior to initiation of adjuvant therapy.
  • The median time from diagnosis of the initial tumor to diagnosis of gliosarcoma was 8.5 months (range 0.5-25 months).
  • All but 1 patient (who only had a biopsy) underwent a second operation for gliosarcoma; 8 patients went on to receive radiotherapy (4 had brachytherapy, 3 had external-beam radiation, and 1 had Gamma Knife surgery); and 14 patients received additional chemotherapy.
  • The median length of survival from the time of gliosarcoma diagnosis was 4.4 months (range 0.7-46 months).
  • There was no difference in time to diagnosis of gliosarcoma in these 2 groups (8 and 8.5 months; p = 0.387).
  • [MeSH-major] Brain Neoplasms / complications. Glioblastoma / complications. Gliosarcoma / etiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Male. Middle Aged. Retrospective Studies


13. Jager B, Schuhmann MU, Schober R, Kortmann RD, Meixensberger J: Induction of gliosarcoma and atypical meningioma 13 years after radiotherapy of residual pilocytic astrocytoma in childhood. Pediatr Neurosurg; 2008;44(2):153-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of gliosarcoma and atypical meningioma 13 years after radiotherapy of residual pilocytic astrocytoma in childhood.
  • In 2004 a second glioma recurrence was partially resected, this time graded gliosarcoma WHO IV.
  • [MeSH-major] Astrocytoma / radiotherapy. Gliosarcoma / etiology. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Radiation-Induced / etiology
  • [MeSH-minor] Adult. Humans. Male. Radiotherapy / adverse effects


14. Rodriguez FJ, Scheithauer BW, Jenkins R, Burger PC, Rudzinskiy P, Vlodavsky E, Schooley A, Landolfi J: Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study. Am J Surg Pathol; 2007 Mar;31(3):351-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study.
  • Only rare examples of gliosarcoma with oligodendroglial components have been reported.
  • Their mean age at diagnosis of gliosarcoma was 48 years (range 36 to 68) (F:M ratio=5:2).
  • [MeSH-major] Brain Neoplasms / pathology. Gliosarcoma / pathology. Neoplasms, Second Primary / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Brain / surgery. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Combined Modality Therapy. Fatal Outcome. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325476.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Han L, Zhang X, Qiu S, Li X, Xiong W, Zhang Y, Qu H, Chang R, Chen B, Wang W, Li S: Magnetic resonance imaging of primary cerebral gliosarcoma: a report of 15 cases. Acta Radiol; 2008 Nov;49(9):1058-67
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of primary cerebral gliosarcoma: a report of 15 cases.
  • CONCLUSION: Gliosarcoma demonstrates certain characteristic MR features, such as supratentorial and peripheral location, well-demarcated, abutting a dural surface, uneven and thick-walled rim-like or ring enhancement, as well as intratumoral strip enhancement.
  • [MeSH-major] Brain Neoplasms / diagnosis. Gliosarcoma / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / pathology. Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / pathology. Corpus Callosum. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18766496.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


16. Cheong JH, Kim CH, Kim JM, Oh YH: Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report. Clin Neurol Neurosurg; 2010 Oct;112(8):701-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report.
  • Gliosarcoma is an uncommon malignant brain tumor composed of distinct sarcomatous and malignant glial cell elements.
  • Pathological examination displayed a biphasic pattern of the glial and sarcomatous components suggesting gliosarcoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Gliosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Neurofibromatosis 1 / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic / pathology. Follow-Up Studies. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Gliosarcoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20466481.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


17. Coulson-Thomas YM, Coulson-Thomas VJ, Filippo TR, Mortara RA, da Silveira RB, Nader HB, Porcionatto MA: Adult bone marrow-derived mononuclear cells expressing chondroitinase AC transplanted into CNS injury sites promote local brain chondroitin sulphate degradation. J Neurosci Methods; 2008 Jun 15;171(1):19-29
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult bone marrow-derived mononuclear cells expressing chondroitinase AC transplanted into CNS injury sites promote local brain chondroitin sulphate degradation.
  • We have produced a vector containing the gene for Flavobacterium heparinum chondroitinase AC for expression in adult bone marrow-derived cells which were then transplanted into an injury site in the CNS.
  • The expression and secretion of active chondroitinase AC was observed in vitro using transfected Chinese hamster ovarian and gliosarcoma cells and in vivo by immunohistochemistry analysis which showed degraded chondroitin sulphate coinciding with the location of transfected bone marrow-derived cells.
  • [MeSH-minor] Animals. Cell Line. Cricetinae. Cricetulus. Female. GAP-43 Protein / metabolism. Gene Expression. Gliosarcoma. Glycosaminoglycans / metabolism. Green Fluorescent Proteins / biosynthesis. Mice. Mice, Inbred C57BL. Mice, Transgenic. Transfection / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417222.001).
  • [ISSN] 0165-0270
  • [Journal-full-title] Journal of neuroscience methods
  • [ISO-abbreviation] J. Neurosci. Methods
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / GAP-43 Protein; 0 / Glycosaminoglycans; 147336-22-9 / Green Fluorescent Proteins; 9007-28-7 / Chondroitin Sulfates; EC 4.2.2.- / Chondroitinases and Chondroitin Lyases
  •  go-up   go-down


18. Salvati M, Caroli E, Raco A, Giangaspero F, Delfini R, Ferrante L: Gliosarcomas: analysis of 11 cases do two subtypes exist? J Neurooncol; 2005 Aug;74(1):59-63
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of this study is to examine clinical, radiological, surgical and therapeutic aspects of 11 patients with gliosarcoma.
  • Between 1993 and 2001, 11 patients with cerebral gliosarcoma were treated at our Institute.
  • [MeSH-major] Brain Neoplasms / pathology. Gliosarcoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078109.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


19. Frank S, Cordier D, Tolnay M, Rosenblum MK: A 28-year-old man with headache, visual and aphasic speech disturbances. Brain Pathol; 2009 Jan;19(1):163-6
MedlinePlus Health Information. consumer health - Headache.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regarding the origin of this recurrent tumor and in reflection of its composition of distinct PXA as well as sarcomatous components, the diagnosis of a pleomorphic xanthoastrosarcoma, to be conceptually considered as a gliosarcoma subtype, was made.To our knowledge, this is an unprecedented case of sarcomatous transformation of a PXA.
  • [MeSH-major] Aphasia / etiology. Brain Neoplasms / diagnosis. Gliosarcoma / diagnosis. Headache / etiology
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Humans. Immunohistochemistry / methods. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Aphasia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19076784.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


20. Agarwal A, Jaye DL, Giegerman CM, Bellamkonda RV: Rational identification of a novel peptide for targeting nanocarriers to 9L glioma. J Biomed Mater Res A; 2008 Dec 1;87(3):728-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report that liposomal nanocarriers coated with a novel oligopeptide enhance uptake by 9L gliosarcoma.
  • In addition, plasma clearance profiles of the RSI peptide coupled liposomal nanocarriers were evaluated in adult immuno-competent rats.
  • [MeSH-major] Drug Carriers / pharmacokinetics. Gliosarcoma / metabolism. Liposomes / pharmacokinetics. Nanostructures. Peptides / pharmacokinetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2008.
  • (PMID = 18200546.001).
  • [ISSN] 1552-4965
  • [Journal-full-title] Journal of biomedical materials research. Part A
  • [ISO-abbreviation] J Biomed Mater Res A
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK064399; United States / NIDDK NIH HHS / DK / DK60647
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Liposomes; 0 / Peptides; 80168379AG / Doxorubicin
  •  go-up   go-down


21. Levin VA, Phuphanich S, Yung WK, Forsyth PA, Maestro RD, Perry JR, Fuller GN, Baillet M: Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol; 2006 Jul;78(3):295-302
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: MT does not improve survival in patients with glioblastoma or gliosarcoma following surgery and radiotherapy.
  • [MeSH-major] Brain Neoplasms / drug therapy. Enzyme Inhibitors / therapeutic use. Glioblastoma / drug therapy. Gliosarcoma / drug therapy. Hydroxamic Acids / therapeutic use. Matrix Metalloproteinase Inhibitors
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Double-Blind Method. Female. Humans. Male. Matrix Metalloproteinases / metabolism. Middle Aged. Musculoskeletal Diseases / chemically induced. Quality of Life. Survival Analysis. Treatment Failure

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636750.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Hydroxamic Acids; 0 / Matrix Metalloproteinase Inhibitors; D5EQV23TDS / marimastat; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


22. Vajtai I, Kuhlen D, Kappeler A, Mariani L, Zimmermann A, Paulus W: Rapid spontaneous malignant progression of supratentorial tanycytic ependymoma with sarcomatous features - "Ependymosarcoma". Pathol Res Pract; 2010 Jul 15;206(7):493-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By analogy to gliosarcoma, the term "ependymosarcoma" has recently been coined to thematize the rare phenomenon of a malignant mesenchymal component arising within an ependymoma.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Ependymoma / pathology. Gliosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Immunophenotyping. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19853384.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Kano T, Ikota H, Wada H, Iwasa S, Kurosaki S: A case of an anaplastic ependymoma with gliosarcomatous components. Brain Tumor Pathol; 2009;26(1):11-7
Genetic Alliance. consumer health - Anaplastic Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical findings showed some parts of the sarcomatous components to stain positively for glial fibrillary acidic protein and, as a result, these sarcomatous components were diagnosed to be gliosarcoma.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Ependymoma / pathology. Gliosarcoma / pathology
  • [MeSH-minor] Adult. Astrocytoma / pathology. Astrocytoma / surgery. Female. Glial Fibrillary Acidic Protein / metabolism. Headache / etiology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Paraffin Embedding. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408092.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


24. Kondo A, Goldman S, Lulla RR, Mania-Farnell B, Vanin EF, Sredni ST, Rajaram V, Soares MB, Tomita T: Longitudinal assessment of regional directed delivery in a rodent malignant glioma model. J Neurosurg Pediatr; 2009 Dec;4(6):592-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rat 9L gliosarcoma cells expressing a luciferase gene were inoculated into adult male rat striata.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Carboplatin / administration & dosage. Drug Delivery Systems / methods. Gliosarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951051.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Luminescent Agents; BG3F62OND5 / Carboplatin; EC 1.13.12.- / Luciferases
  •  go-up   go-down


25. Karremann M, Rausche U, Fleischhack G, Nathrath M, Pietsch T, Kramm CM, Wolff JE: Clinical and epidemiological characteristics of pediatric gliosarcomas. J Neurooncol; 2010 Apr;97(2):257-65
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliosarcoma (GS) is a glioblastoma with a sarcomatous component that is presumed to be a metaplastic differentiation of glioma cells.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / pathology. Gliosarcoma / epidemiology. Gliosarcoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Kaplan-Meier Estimate. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19806321.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Miyatake S, Kawabata S, Kajimoto Y, Aoki A, Yokoyama K, Yamada M, Kuroiwa T, Tsuji M, Imahori Y, Kirihata M, Sakurai Y, Masunaga S, Nagata K, Maruhashi A, Ono K: Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg; 2005 Dec;103(6):1000-9
Hazardous Substances Data Bank. BORON COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Thirteen patients, 10 of whom harbored a glioblastoma multiforme (GBM), one a gliosarcoma, one an anaplastic astrocytoma, and one an anaplastic oligoastrocytoma, were treated using this modified BNCT between January 2002 and December 2003.
  • [MeSH-minor] Adult. Aged. Astrocytoma / radiotherapy. Boron Compounds / therapeutic use. Brain Edema / diagnosis. Brain Edema / etiology. Female. Glioblastoma / radiotherapy. Gliosarcoma / radiotherapy. Humans. Male. Middle Aged. Neutrons. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381186.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boron Compounds
  •  go-up   go-down


27. Grosu AL, Weber WA, Franz M, Stärk S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C: Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Oct 1;63(2):511-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The trial included a total of 44 patients with recurrent high-grade gliomas (1 patient with anaplastic oligodendroglioma, 8 with anaplastic astrocytoma, 33 with glioblastoma multiforme, and 2 with gliosarcoma) after previous surgery and postoperative conventional radiotherapy +/- chemotherapy.
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radionuclide imaging. Astrocytoma / radiotherapy. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Dose Fractionation. Female. Glioblastoma / drug therapy. Glioblastoma / radionuclide imaging. Glioblastoma / radiotherapy. Gliosarcoma / drug therapy. Gliosarcoma / radionuclide imaging. Gliosarcoma / radiotherapy. Humans. Male. Methionine. Middle Aged. Oligodendroglioma / drug therapy. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / radiotherapy. Positron-Emission Tomography / methods. Prospective Studies. Statistics, Nonparametric. Stereotaxic Techniques. Tomography, Emission-Computed, Single-Photon / methods. alpha-Methyltyrosine

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168843.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 658-48-0 / alpha-Methyltyrosine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; AE28F7PNPL / Methionine
  •  go-up   go-down


28. Brown PD, Jensen AW, Felten SJ, Ballman KV, Schaefer PL, Jaeckle KA, Cerhan JH, Buckner JC: Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol; 2006 Dec 1;24(34):5427-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: There is growing recognition that the primary cause of cognitive deficits in adult patients with primary brain tumors is the tumor itself and more significantly, tumor progression.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Cognition Disorders / etiology. Glioma / complications. Gliosarcoma / complications
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17135644.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35415; United States / NCI NIH HHS / CA / CA-37404
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Lusis EA, Travers S, Jost SC, Perry A: Glioblastomas with giant cell and sarcomatous features in patients with Turcot syndrome type 1: a clinicopathological study of 3 cases. Neurosurgery; 2010 Sep;67(3):811-7; discussion 817
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Neoplasms / pathology. Giant Cells / pathology. Glioblastoma / pathology. Gliosarcoma / pathology. Sarcoma / pathology
  • [MeSH-minor] Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Female. Humans. Male. Middle Aged. Neoplastic Syndromes, Hereditary / diagnosis. Neoplastic Syndromes, Hereditary / genetics. Neoplastic Syndromes, Hereditary / pathology. Retrospective Studies. Young Adult


30. Hau P, Kunz-Schughart LA, Rümmele P, Arslan F, Dörfelt A, Koch H, Lohmeier A, Hirschmann B, Müller A, Bogdahn U, Bosserhoff AK: Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas. J Neurooncol; 2006 Mar;77(1):1-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Child. Disease Progression. Gene Expression Regulation, Neoplastic. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / pathology. Gliosarcoma / genetics. Gliosarcoma / metabolism. Gliosarcoma / pathology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. RNA, Messenger / analysis. Time Factors. Transforming Growth Factor beta1. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292494.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / RNA, Messenger; 0 / TGFB1 protein, human; 0 / Tenascin; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


31. Magalhaes A, Godfrey W, Shen Y, Hu J, Smith W: Proton magnetic resonance spectroscopy of brain tumors correlated with pathology. Acad Radiol; 2005 Jan;12(1):51-7
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Astrocytoma / diagnosis. Astrocytoma / pathology. Brain / pathology. Choline / analysis. Creatine / analysis. Female. Glioblastoma / diagnosis. Glioblastoma / pathology. Glioma / diagnosis. Glioma / pathology. Gliosarcoma / diagnosis. Gliosarcoma / pathology. Humans. Hydrogen. Image Processing, Computer-Assisted / methods. Male. Middle Aged. Oligodendroglioma / diagnosis. Oligodendroglioma / pathology. Protons

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROGEN .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691725.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 30KYC7MIAI / Aspartic Acid; 7YNJ3PO35Z / Hydrogen; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


32. Kleinschmidt-DeMasters BK, Meltesen L, McGavran L, Lillehei KO: Characterization of glioblastomas in young adults. Brain Pathol; 2006 Oct;16(4):273-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most adult glioblastoma multiformes (GBMs) present in patients 45-70 years old; tumors occurring at the extremes of the adult age spectrum are uncommon, and seldom studied.
  • We hypothesized that young-adult GBMs would differ from elderly-adult and from pediatric GBMs.
  • Twenty-eight (74%) of our 38 young-adult GBM patients had primary de novo tumors, two of which occurred in patients with cancer syndromes.
  • Six of 38 cases manifested unusual morphological features, including three epithelioid GBMs, one rhabdoid GBM, one gliosarcoma and one small cell GBM containing abundant, refractile, eosinophilic inclusions.
  • GBMs in young adults are a more inhomogeneous tumor group than GBMs occurring in older adult patients and show features that overlap with both pediatric and adult GBMs.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Ki-67 Antigen / metabolism. Male. Mitotic Index. Neoplasms, Radiation-Induced. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / pathology. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Survival Analysis. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107596.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


33. Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stávale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C: EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res; 2009 Sep 15;15(18):5753-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The epidermal growth factor receptor (EGFR) is amplified and overexpressed in adult glioblastoma, with response to targeted inhibition dependent on the underlying biology of the disease.
  • No kinase or extracellular domain mutations were observed; however, 6 of 35 (17%) cases harbored the EGFRvIII deletion, including two anaplastic oligodendrogliomas and a gliosarcoma overexpressing EGFRvIII in the absence of gene amplification and coexpressing platelet-derived growth factor receptor alpha.

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2009 Nov 15;15(22):7110
  • (PMID = 19737945.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C1178/A10294; United Kingdom / Cancer Research UK / / C309/A2187; United Kingdom / Cancer Research UK / / C309/A8274
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0 / epidermal growth factor receptor VIII; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


34. Deb P, Sharma MC, Mahapatra AK, Agarwal D, Sarkar C: Glioblastoma multiforme with long term survival. Neurol India; 2005 Sep;53(3):329-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One was a giant cell GBM, which progressed to gliosarcoma on recurrence.
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Brain Neoplasms / physiopathology. Child. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Survivors


35. Barth RF, Kaur B: Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol; 2009 Sep;94(3):299-312
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The C6, 9L and T9 gliomas were induced by repeated injections of methylnitrosourea (MNU) to adult rats.
  • The 9L gliosarcoma has been used widely and has provided important information relating to brain tumor biology and therapy.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2004 Nov;101(5):826-31 [15540922.001]
  • [Cites] Mol Ther. 2004 Dec;10(6):1071-84 [15564139.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8561-76 [15623640.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):341-50 [15671565.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2533-43 [15728459.001]
  • [Cites] Mol Cancer. 2005;4(1):12 [15762988.001]
  • [Cites] Brain Res Mol Brain Res. 2005 Apr 27;135(1-2):93-103 [15857672.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3475-84 [15867250.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3821-7 [15897582.001]
  • [Cites] J Neurooncol. 2005 May;72(3):209-15 [15937642.001]
  • [Cites] Brain Res. 2005 Jun 14;1047(1):56-64 [15893739.001]
  • [Cites] Am J Pathol. 2005 Aug;167(2):565-76 [16049340.001]
  • [Cites] J Neurosurg. 2005 Jan;102(1 Suppl):53-8 [16206734.001]
  • [Cites] Neurosurg Focus. 2005 Oct 15;19(4):E1 [16241103.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):603-11 [16338098.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):52-9 [16432162.001]
  • [Cites] J Neurosurg. 2006 Jan;104(1):118-28 [16509155.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):133-48 [17874037.001]
  • [Cites] Neurochem Res. 2007 Dec;32(12):2235-42 [17701349.001]
  • [Cites] Free Radic Biol Med. 2008 Jan 1;44(1):63-72 [18045548.001]
  • [Cites] J Natl Cancer Inst. 2007 Dec 5;99(23):1768-81 [18042934.001]
  • [Cites] J Neurooncol. 2008 Jan;86(1):13-21 [17611717.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):883-91 [18245552.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):320-9 [18240929.001]
  • [Cites] Phys Med Biol. 2008 Feb 21;53(4):861-78 [18263945.001]
  • [Cites] Int J Immunopathol Pharmacol. 2008 Jan-Mar;21(1):227-31 [18336750.001]
  • [Cites] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1977 Aug 15;89(3):273-95 [198983.001]
  • [Cites] J Neurosurg. 1979 Mar;50(3):298-304 [217977.001]
  • [Cites] Acta Neuropathol. 1980;51(1):23-31 [7435138.001]
  • [Cites] J Neurosurg. 1980 Dec;53(6):808-15 [7003068.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Sep;18(9):891-5 [6891332.001]
  • [Cites] J Neuropathol Exp Neurol. 1983 Mar;42(2):122-35 [6600780.001]
  • [Cites] J Neuropathol Exp Neurol. 1984 Jul;43(4):426-38 [6610726.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5276-81 [3019523.001]
  • [Cites] Cancer. 1987 Jan 15;59(2):266-70 [3026604.001]
  • [Cites] Ann Neurol. 1987 Sep;22(3):300-5 [3118762.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2373-8 [2015600.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2430-7 [2015604.001]
  • [Cites] J Clin Neurosci. 2008 May;15(5):545-51 [18378459.001]
  • [Cites] J Neurooncol. 2008 May;88(1):1-9 [18228115.001]
  • [Cites] Neuroimage. 2008 Apr 1;40(2):973-83 [18441552.001]
  • [Cites] J Neurosurg. 2008 May;108(5):972-8 [18447715.001]
  • [Cites] J Chemother. 2008 Apr;20(2):253-62 [18467254.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Jun;35(6):1192-203 [18264706.001]
  • [Cites] Toxicol Lett. 2008 Jun 10;179(1):29-33 [18485629.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5508-11 [18632599.001]
  • [Cites] Neuro Oncol. 2008 Jun;10(3):292-9 [18430796.001]
  • [Cites] J Cereb Blood Flow Metab. 2008 Aug;28(8):1431-9 [18414496.001]
  • [Cites] Brain Res. 2008 Aug 28;1227:198-206 [18602898.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2008 Jul-Aug;44(7):280-9 [18594936.001]
  • [Cites] J Neurooncol. 2008 Oct;90(1):19-24 [18594766.001]
  • [Cites] Eur J Pharm Biopharm. 2008 Sep;70(1):66-74 [18555675.001]
  • [Cites] Cancer Gene Ther. 2008 Oct;15(10):685-92 [18535615.001]
  • [Cites] Neurol Res. 2008 Jun;30(5):511-7 [18953742.001]
  • [Cites] NMR Biomed. 2008 Nov;21(10):1043-56 [18615861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):530-6 [19147017.001]
  • [Cites] Eur J Radiol. 2009 Apr;70(1):180-9 [18541399.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):326-33 [10659021.001]
  • [Cites] IEEE Trans Biomed Eng. 2000 Feb;47(2):259-65 [10721633.001]
  • [Cites] Clin Exp Metastasis. 1992 Sep;10(5):345-50 [1505124.001]
  • [Cites] J Neurooncol. 1991 Dec;11(3):185-97 [1823340.001]
  • [Cites] Int J Cancer. 1992 Sep 30;52(3):409-13 [1399117.001]
  • [Cites] Cancer Res. 1993 Jan 1;53(1):176-82 [8416743.001]
  • [Cites] Science. 1993 Jan 1;259(5091):94-7 [8418502.001]
  • [Cites] J Neurosurg. 1993 Nov;79(5):729-35 [8410252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Mar 30;28(5):1067-77 [8175391.001]
  • [Cites] J Neurooncol. 1994;19(3):259-68 [7807177.001]
  • [Cites] J Neurooncol. 1994;22(3):191-200 [7760095.001]
  • [Cites] J Surg Oncol. 1995 Jun;59(2):105-9 [7776650.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):607-14 [7669569.001]
  • [Cites] Leukemia. 1995 Oct;9 Suppl 1:S106-12 [7475300.001]
  • [Cites] Int J Cancer. 1995 Sep 15;62(6):767-71 [7558428.001]
  • [Cites] Hum Gene Ther. 1995 Nov;6(11):1467-76 [8573619.001]
  • [Cites] Cancer Lett. 1997 May 1;115(1):81-90 [9097982.001]
  • [Cites] Invasion Metastasis. 1996;16(3):107-15 [9186546.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):275-7 [9293462.001]
  • [Cites] J Neurooncol. 1998 Jan;36(1):91-102 [9525831.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2020-8 [9581848.001]
  • [Cites] Hum Gene Ther. 1999 Jan 1;10(1):95-101 [10022534.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3861-5 [10463570.001]
  • [Cites] Cancer Gene Ther. 2004 Nov;11(11):721-32 [15475879.001]
  • [Cites] Pathobiology. 1999 Jul-Aug;67(4):202-6 [10738182.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):993-9 [10871746.001]
  • [Cites] Cancer Gene Ther. 2000 Jun;7(6):879-84 [10880018.001]
  • [Cites] Cancer Gene Ther. 2000 Jun;7(6):947-53 [10880027.001]
  • [Cites] J Neurooncol. 2000;46(3):231-40 [10902854.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):22695-703 [10801887.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):993-9; discussion 999-1000 [11014444.001]
  • [Cites] Cancer Gene Ther. 2001 Jan;8(1):3-8 [11219491.001]
  • [Cites] Neurol Res. 2001 Jun;23(4):359-66 [11428516.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):37-47 [11451201.001]
  • [Cites] Histol Histopathol. 2001 Jul;16(3):735-44 [11510963.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7056-9 [11585735.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):275-87 [11718260.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):1-12 [11949821.001]
  • [Cites] Gene Ther. 2002 May;9(9):584-91 [11973634.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):143-8 [11995815.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Jun;301(3):838-51 [12023511.001]
  • [Cites] Med Oncol. 2002;19(1):1-9 [12025885.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):725-35 [12152787.001]
  • [Cites] Gene Ther. 2002 Sep;9(17):1139-45 [12170377.001]
  • [Cites] Cancer Lett. 2003 Mar 20;192(1):97-107 [12637158.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1083-93 [12651601.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):17-22 [12659666.001]
  • [Cites] J Neurooncol. 2003 Mar-Apr;62(1-2):61-74 [12749703.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3195-201 [12810648.001]
  • [Cites] J Neurooncol. 2003 May;63(1):1-7 [12814248.001]
  • [Cites] Ann Neurol. 2003 Sep;54(3):388-92 [12953273.001]
  • [Cites] Cell Immunol. 2003 Oct;225(2):113-21 [14698145.001]
  • [Cites] Gene Ther. 2004 Jan;11(2):161-9 [14712300.001]
  • [Cites] Gene Ther. 2004 Jan;11(2):214-23 [14712306.001]
  • [Cites] Mol Ther. 2004 Feb;9(2):282-91 [14759812.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2317-23 [15059878.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jul;146(7):731-4 [15197617.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5187-201 [15297423.001]
  • [Cites] Science. 1968 Jul 26;161(3839):370-1 [4873531.001]
  • [Cites] J Cell Physiol. 1970 Jun;75(3):329-39 [4988781.001]
  • [Cites] J Neurosurg. 1971 Mar;34(3):310-23 [4323142.001]
  • [Cites] J Neurosurg. 1971 Mar;34(3):335-40 [5547317.001]
  • [Cites] Cancer Res. 1973 May;33(5):976-86 [4703128.001]
  • [Cites] J Med. 1975;6(3-4):249-59 [1059719.001]
  • [Cites] J Natl Cancer Inst. 1975 Nov;55(5):1177-87 [1206744.001]
  • [Cites] Am J Pathol. 1976 Apr;83(1):149-76 [179328.001]
  • [Cites] Can J Neurol Sci. 2006 Feb;33(1):86-91 [16583728.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E25 [16709031.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):989-98 [16741309.001]
  • [Cites] J Neurosci. 2006 Jun 21;26(25):6781-90 [16793885.001]
  • [Cites] J Neurooncol. 2006 Aug;79(1):9-17 [16575532.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5288-97 [17000661.001]
  • [Cites] NMR Biomed. 2006 Dec;19(8):1035-42 [16894643.001]
  • [Cites] Childs Nerv Syst. 2006 Dec;22(12):1519-25 [17021732.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):149-62 [16941073.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1260-8 [17317838.001]
  • [Cites] J Magn Reson. 2007 May;186(1):150-5 [17303454.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2728-37 [17473206.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4541-4 [17510377.001]
  • [Cites] Mol Ther. 2007 Jul;15(7):1373-81 [17457322.001]
  • [Cites] Stem Cells. 2007 Jul;25(7):1645-53 [17412894.001]
  • [Cites] Behav Brain Res. 2007 Aug 22;182(1):42-50 [17572515.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2290-302 [17699724.001]
  • [Cites] Neoplasia. 2007 Jul;9(7):546-55 [17710157.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5195-201 [17726137.001]
  • [Cites] Magn Reson Med. 2007 Sep;58(3):454-62 [17763344.001]
  • [Cites] Can J Neurol Sci. 2007 Aug;34(3):296-306 [17803026.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):191-202 [17557137.001]
  • (PMID = 19381449.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA150153; United States / NINDS NIH HHS / NS / R01 NS064607; United States / NINDS NIH HHS / NS / R21 NS056203; United States / NINDS NIH HHS / NS / K01 NS059575; United States / NINDS NIH HHS / NS / K01 NS059575-02; United States / NINDS NIH HHS / NS / R01 NS064607-01; United States / NINDS NIH HHS / NS / R21 NS056203-02
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 149
  • [Other-IDs] NLM/ NIHMS127810; NLM/ PMC2730996
  •  go-up   go-down


36. Schiopu C, Flangea C, Capitan F, Serb A, Vukelić Z, Kalanj-Bognar S, Sisu E, Przybylski M, Zamfir AD: Determination of ganglioside composition and structure in human brain hemangioma by chip-based nanoelectrospray ionization tandem mass spectrometry. Anal Bioanal Chem; 2009 Dec;395(8):2465-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unlike the case of previously investigated high malignancy gliosarcoma, in HFC one modified O-Ac-GD2 and one modified O-Ac-GM4 gangliosides were observed.
  • [MeSH-minor] Adult. Brain / metabolism. Case-Control Studies. Cerebral Cortex / metabolism. Frontal Lobe / metabolism. Humans. Isomerism. Male. N-Acetylneuraminic Acid / analysis. Nanotechnology

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19841910.001).
  • [ISSN] 1618-2650
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gangliosides; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


37. Murphy S, Boyle FM, Davey RA, Gu XQ, Mather LE: Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. J Pharm Pharmacol; 2007 Jan;59(1):105-14
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adult female F344 rats were implanted with 9L gliosarcoma tumours intracranially, subcutaneously (flank), or both.

  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227627.001).
  • [ISSN] 0022-3573
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


38. Tang P, Roldan G, Brasher PM, Fulton D, Roa W, Murtha A, Cairncross JG, Forsyth PA: A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol; 2006 Jul;78(3):311-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological subtypes were: 16 (59%) glioblastoma multiforme (GBM), malignant astrocytoma (5 patients), malignant mixed glioma (5 patients), and glioblastoma/gliosarcoma (1 patient).
  • [MeSH-minor] Adult. Aged. Anorexia / chemically induced. Carboplatin / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Fatigue / chemically induced. Female. Headache / chemically induced. Humans. Male. Middle Aged. Nausea / chemically induced. Tamoxifen / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710748.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; BG3F62OND5 / Carboplatin
  •  go-up   go-down


39. Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, Musib L, Nicol SJ, Thornton DE, Prados MD: Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol; 2010 Jun;12(6):608-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a phase I study to determine the safety and recommended phase II dose of enzastaurin (oral inhibitor of the protein kinase C-beta [PKCbeta] and the PI3K/AKT pathways) when given in combination with radiation therapy (RT) plus temozolomide to patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Female. Humans. Indoles / administration & dosage. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest New Drugs. 1999;17(3):227-40 [10665476.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1275-9 [19188675.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5954-8 [11085511.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3369-75 [12960124.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Feb;53(2):133-40 [14593497.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):816-26 [9669344.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4413-8 [10485491.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):47720-5 [15364915.001]
  • [Cites] Oncogene. 2004 Dec 2;23(56):9062-9 [15489897.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7462-9 [16103100.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4092-9 [16943527.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):689-700 [17108987.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):47-52 [17108062.001]
  • [Cites] Ann Neurol. 2007 Feb;61(2):153-61 [17212356.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4474-81 [17671132.001]
  • [Cites] J Clin Pharmacol. 2007 Sep;47(9):1138-51 [17766700.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4127-36 [17827463.001]
  • [Cites] J Neurooncol. 2000 Apr;47(2):109-15 [10982151.001]
  • (PMID = 20156802.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; UC96G28EQF / enzastaurin
  • [Other-IDs] NLM/ PMC2940647
  •  go-up   go-down


40. Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS, O'Fallon JR, North Central Cancer Treatment Group 93-72-52, Southwest Oncology Group 9503 Trials: Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol; 2006 Aug 20;24(24):3871-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: After surgery, patients were stratified by age, performance score, extent of surgical resection, and histology (glioblastoma v gliosarcoma) and then randomly assigned to arm A (BCNU plus SRT), arm B (BCNU plus ART), arm C (cisplatin plus BCNU plus SRT), or arm D (cisplatin plus BCNU plus ART).
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921039.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35090; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35272; United States / NCI NIH HHS / CA / CA-35415; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-45450; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63826; United States / NCI NIH HHS / CA / CA-63844; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


41. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD: Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol; 2006 Jan 1;24(1):115-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: In this phase II trial, 100 mCi of 131I-m81C6 was injected directly into the surgically created resection cavity (SCRC) of 43 patients with recurrent malignant glioma (glioblastoma multiforme [GBM], n = 33; anaplastic astrocytoma [AA], n = 6; anaplastic oligodendroglioma [AO], n = 2; gliosarcoma [GS], n = 1; and metastatic adenocarcinoma, n = 1) followed by chemotherapy.
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Mar 20;24(9):1484. Guruangan, Sri [corrected to Gururangan, Sridharan]
  • (PMID = 16382120.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1-P50-CA108786-01; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Iodine Radioisotopes; 0 / Tenascin
  •  go-up   go-down






Advertisement